Gatipotuzumab - Glycotope
Alternative Names: Anti-TA-MUC1 monoclonal antibody - Glycotope; GlycoOptimised IgG1 antibody - Glycotope; GT-MAB 2.5-GEX™; PankoMab; PankoMab-GEX; Trifunctional antibody - GlycotopeLatest Information Update: 28 Jun 2023
At a glance
- Originator NEMOD Biotherapeutics [CEASED]
- Developer Glycotope
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Apoptosis stimulants; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- No development reported Solid tumours
Most Recent Events
- 28 Jun 2023 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Germany (IV, Infusion)
- 28 Jun 2023 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Italy (IV, Infusion)
- 28 Jun 2023 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Spain (IV, Infusion)